DURECT Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

$DRRX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $DRRX alert in real time by email
8-K
0001082038false00010820382025-02-142025-02-14

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

February 14, 2025

Date of Report

(Date of earliest event reported)

 

DURECT CORPORATION

(Exact name of Registrant as specified in its charter)

 

Delaware

 

000-31615

 

94-3297098

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

10240 Bubb Road

Cupertino, CA 95014

(Address of principal executive offices) (Zip code)

(408) 777-1417

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock $0.0001 par value per share

Preferred Share Purchase Rights

 

DRRX

The NASDAQ Stock Market LLC

(The Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b) On February 14, 2025, Terrence F. Blaschke announced his intention to retire and submitted his immediately effective resignation from the Board of Directors (the “Board”) of DURECT Corporation (the “Company”), including from his role as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”).

Dr. Blaschke’s decision to resign was not the result of any disagreement with management or the Board, on any matter relating to the Company’s operations, policies, or practices.

 

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

 

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

DURECT Corporation

 

 

 

 

 

Date: February 21, 2025

 

By:

 

/s/ James E. Brown

 

 

 

 

    James E. Brown

    President and Chief Executive Officer

 

 

 

 

 

 

3


Get the next $DRRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DRRX

DatePrice TargetRatingAnalyst
More analyst ratings

$DRRX
Press Releases

Fastest customizable press release news feed in the world

See more
  • DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

    CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

    CUPERTINO, Calif., Feb. 4, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, to be held virtually, February 11-12, 2025. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer." alt="DURECT Corporation (www.durect.com) is a late-stage biopharmaceutical company pion

    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$DRRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$DRRX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$DRRX
SEC Filings

See more

$DRRX
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for POSIMIR

    Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$DRRX
Leadership Updates

Live Leadership Updates

See more
  • KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

    KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

    $AVTX
    $DRRX
    $HALO
    $MESO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Medicinal Chemicals and Botanical Products
  • DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

    CUPERTINO, Calif., March 21, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.  Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election and will retire from the board on June 21, 2023 when his current term as a board member expires.    "We thank Dave for his many years of service on the DURECT Board and wish him well," stated James E. Brown, D.V.M., President and CEO of DURECT.  "Gail is a seasoned biopharmaceutical executive and we have benefitted from her innovative and strategic thinking as a board member since January

    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

    CUPERTINO, Calif., July 5, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment of Timothy M. Papp as its Chief Financial Officer. In this new role, Mr. Papp will direct and oversee all financial and capital markets activities including accounting, financial reporting, financial planning and analysis, financial strategy, and investor relations. "We are excited to welcome Tim to our executive leadership team, as he brings his deep understanding of corporate finance and corporate value drivers to DURECT," stated James E. Brown,

    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$DRRX
Financials

Live finance-specific insights

See more
  • DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

    CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

    -     Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation -     Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif., Nov. 13, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute o

    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$DRRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more